Answers are grounded in this paper and cite their sources.
Genomic instability is one of the hallmarks of cancer, and alterations in DNA damage response genes have been associated with sensitivity to immuno-oncology modulators (Mouw et al., 2017). Cutaneous malignant melanoma (CMM) is the cancer with the highest median tumor mutation burden (Alexandrov et al., 2013). Tumor mutation burden and DNA damage response have been demonstrated to have an impact on disease progression and therapy efficacy in CMM.
No takes yet. Share an insight, caveat, or question.
Das et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: